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Introduction
Lung infections with Pseudomonas aeruginosa constitute
the predominant disease phenotype in cystic fibrosis
(CF) patients (1). Despite a vigorous and rapid influx of
functional peripheral blood neutrophils into infected CF
airways (2) accompanied by the production of high titers
of specific Ab’s, P. aeruginosa infections become chronic
(3), airways are destroyed, and lung function declines.
Several hypotheses have been offered to explain the
failure of mucosal defense and the high prevalence of
P. aeruginosa in the CF lung. Most hypotheses have
focused on bacterial infection of CF airway epithelia,
mediated by an increased binding of P. aeruginosa to
the surfaces of CF airway epithelial cells (4, 5)
impaired internalization and killing of P. aeruginosa by
CF airway epithelia due to the absence of cystic fibro-
sis transmembrane conductance regulator (CFTR) at
the apical surface (6), or “high-salt”–mediated
defensin inactivation (7). In contrast, the reduced air-
way surface liquid (ASL) volume (impaired mucus
clearance) hypothesis predicts infection by P. aerugi-
nosa and other pathogens of stationary mucus adher-
ent to airway surfaces.
As an approach to distinguish among these hypothe-
ses, we sought to identify the site of P. aeruginosa infec-
tion in freshly excised CF airways, differentiating
between the intraluminal (mucus) and epithelial surface
compartments. Based on our observations that 
P. aeruginosa resided in the intraluminal contents, we
asked what conditions confronted P. aeruginosa in this
microenvironment in vivo in CF patients, focusing on
O2 availability. We extended these studies to investigate
in vitro whether airway mucus hypoxia (O2 gradients)
was present in thickened CF mucus before infection and
whether steep O2 gradients within mucus were unique
to the CF genotype. Finally, we explored the hypotheses
that (a) bacteria deposited on airway surfaces penetrate
into hypoxic mucus, and (b) P. aeruginosa responses to
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Current theories of CF pathogenesis predict different predisposing “local environmental” conditions
and sites of bacterial infection within CF airways. Here we show that, in CF patients with established
lung disease, Psuedomonas aeruginosa was located within hypoxic mucopurulent masses in airway
lumens. In vitro studies revealed that CF-specific increases in epithelial O2 consumption, linked to
increased airway surface liquid (ASL) volume absorption and mucus stasis, generated steep hypoxic
gradients within thickened mucus on CF epithelial surfaces prior to infection. Motile P. aeruginosa
deposited on CF airway surfaces penetrated into hypoxic mucus zones and responded to this envi-
ronment with increased alginate production. With P. aeruginosa growth in oxygen restricted envi-
ronments, local hypoxia was exacerbated and frank anaerobiosis, as detected in vivo, resulted. These
studies indicate that novel therapies for CF include removal of hypoxic mucus plaques and antibi-
otics effective against P. aeruginosa adapted to anaerobic environments.
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hypoxia, e.g., increased alginate production, may favor
its persistence in the CF lung.
Methods
Study subjects: normal, CF, and disease controls. Lungs
from seven CF patients chronically infected with P.
aeruginosa were obtained for morphometric analyses
after lung transplantation (five males and two females,
mean age 29.5 years; Cystic Fibrosis/Pulmonary
Research and Treatment Center, University of North
Carolina, Chapel Hill, Chapel Hill, North Carolina,
USA) or after lobectomy (two females, mean age 8
years; Service de Pédiatrie, Centre Hospitalier Lyon-
Sud, Pierre-Bénite, France). Nasal polyps from four CF
patients (mean age 14.3 years; Ear, Nose and Throat
Clinic, Klinikum Ludwigshafen, Germany), and from
four non-CF individuals (mean age 46.5 years; Ear,
Nose and Throat Clinic, University of Tübingen, Ger-
many) were used for spheroid cell cultures. Cells for
planar cell cultures were obtained from seven normal
lung transplant donors (four males, three females,
mean age 42 ± 6 years), eight CF lung transplant recip-
ients (four males, three females, mean age 34 ± 3 years),
and two primary ciliary dyskinesia (PCD) lung trans-
plant recipients (one male, one female, ages 15 and 50
years, respectively). For in vivo oxygen partial pressure
(pO2) measurements, six CF patients (two males, four
females, mean age 23.8 years; mean forced expiratory
volume in one second, 55.7% predicted) were studied.
Data were successfully obtained from three patients.
Informed consent was obtained from all patients
and/or parents, and all parts of the study were
approved by the local ethical committees.
Bacterial strains. PAO1 (8) bacteria were grown for adhe-
sion experiments in vitro overnight at 37°C in 5 ml
Trypticase soy broth (TSB; Oxoid Ltd., Basingstoke,
United Kingdom). A bacterial suspension (10–50 µl) of
the overnight culture (OD600nm 0.05) was inoculated
into 5 ml fresh TSB medium and the bacteria cultured
until the OD600nm of 1.5 was reached. For confocal
microscopy studies, the P. aeruginosa strain ATCC 27853
was used. For alginate measurements, 15 genetically dif-
ferent non-CF (environmental) strains of P. aeruginosa as
well as PAO1 were analyzed, and for growth in ASL,
PAO1 and P. aeruginosa ATCC 700829 were tested. PAO1
grown in TSB was used for O2 measurements.
Microscopy of lung sections. Immediately after resection,
lung tissues were cut into 0.5-cm3 cubes and fixed in
2.5% glutaraldehyde, 10% formaldehyde, or shock-
frozen in liquid nitrogen. For immunofluorescence,
thin sections (5–10 µm) were prepared from shock-
frozen lung tissues and P. aeruginosa identified in
bronchi/bronchioli with polyclonal rabbit IgG specif-
ic for whole P. aeruginosa cells; then incubation
occurred with indocarbocyanin-conjugated (Cy3-con-
jugated) goat anti-rabbit IgG (Dianova, Hamburg,
Germany), diluted 1:500. Eight sections from each of
nine separate CF lung samples (72 sections total) were
analyzed for P. aeruginosa location, using the KS300
Imaging System (Kontron Electronic GmbH, Eching,
Germany). For transmission electron microscopy
(TEM), segmental bronchi (∼6.5-mm sections) from
nine CF lungs were postfixed in OSO4, thin sections
cut, and uracyl acetate/lead citrate stained. For scan-
ning electron micrographs, specimens were processed
as described previously (9). Squares (406) from 14
bronchi from two CF lungs were analyzed for binding
of P. aeruginosa to the epithelium.
Adhesion of P. aeruginosa to mucus adherent to primary
nasal epithelial spheroids. The spheroid cell culture system
was used as described previously (9). To collect secret-
ed mucus, spheroids were incubated in DMEM/Ham’s
F12 medium (Life Technologies Inc., Heidelberg, Ger-
many) depleted of antibiotics and antimycotics for 5
days, supernatant collected by centrifugation (225 g),
and stored at –20°C until use.
Spheroids (8 weeks; four CF and four normal [NL]),
suspended in DMEM/Ham’s F12 medium, were incu-
bated with P. aeruginosa at a cell/bacteria ratio of 1:100
for 2 hours/37°C/5% CO2. In some experiments,
mucus was removed from spheroids by prewashing
with PBS. After incubation with P. aeruginosa, spheroids
were washed using a cell strainer (Becton Dickinson,
Heidelberg, Germany). Twenty to 30 spheroids per
individual were analyzed for adherence of P. aeruginosa
by scanning electron microscopy (9).
P. aeruginosa was incubated with spheroid supernatants
containing mucus for 2 hours at 37°C/5% CO2. After
washing, bacteria were fixed on coverslips, incubated
with a mAb to human mucins, washed, incubated with
a Cy3-conjugated goat anti-mouse IgG (DAKO Corp.,
Hamburg, Germany) for 40 minutes at 23°C, washed
with water, and embedded in Permafluor (Sigma Chem-
ical Co., St. Louis, Missouri, USA).
Fiberoptic bronchoscopy. Fiberoptic bronchoscopy was
performed as described previously (2) with minor mod-
ifications. For in vivo pO2 measurements, a computer-
ized Clark type oxygen probe (length: 65 cm; outer
diameter: 2 mm; inner diameter: 0.4 mm; Licox pO2;
GMS, Kiel, Germany) was fixed to the tip of the bron-
choscope and guided under video control into right
upper lobes obstructed with mucopurulent material.
Planar, primary bronchial culture system. Human airway
epithelial cells were obtained from freshly excised
bronchi by protease digestion (10), seeded directly on 12-
mm Transwell Col membranes (Corning-Costar Corp.,
Cambridge, Massachusetts, USA) in modified bronchial
epithelial growth medium under air-liquid interface
conditions and studied when fully differentiated (2–5
weeks; transepithelial resistance of ≥ 350 Ω cm2).
Measurement of ASL pO2–planar bronchial cultures. O2
microelectrodes were purchased from Diamond Gen-
eral Development Corp. (Ann Arbor, Michigan, USA).
The O2 microelectrode and 3 M KCl reference electrode
were advanced into ASL with micromanipulators as
described previously (11).
Confocal microscopy measurements of ASL/P. aeruginosa.
PBS (30 µl) containing 2 mg/ml Texas Red-dextran (10
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kDa; Molecular Probes Inc., Eugene, Oregon, USA)
was added to CF cultures 2–48 hours before the addi-
tion of bacteria or fluorescent beads (1 µm; Molecular
Probes Inc.) as described previously (12). For all stud-
ies, perfluorocarbon (FC-77, 3M Co., St. Paul, Min-
nesota, USA) was added to the mucus surface to pre-
vent ASL evaporation.
P. aeruginosa bacteria were suspended in 3 ml PBS
(OD470 of 0.15 [∼107 CFU/ml]) and incubated with 5 µM
SYTO 13 (Molecular Probes Inc.) for 1 hour at 37°C. The
bacterial suspension was washed once in PBS, cen-
trifuged, and the pellet resuspended in PBS (100 µl).
Bacterial growth and production of alginate by P. aeruginosa
in aerobic and anaerobic culture conditions. To determine
whether P. aeruginosa is able to grow in freshly harvest-
ed ASL from CF and NL well-differentiated cultures
(11) under aerobic and anaerobic (anaerobic chamber
from Coy Laboratory Products, Gross Lake, Michigan,
USA) conditions, a small number of bacteria (∼100–200
CFU/0.5 µl) of PAO1 or the environmental P. aeruginosa
strain (ATCC 700829) was added to 30 µl of ASL in par-
allel in two titer plates. For these experiments, the bac-
teria were grown on sheep blood agar overnight, sus-
pended in PBS, with this suspension adjusted to an
OD470nm of 0.15, diluted 1:100 in PBS, and starved for 2
hours before addition to ASL. Titer plates were incu-
bated aerobically and anaerobically for 72 hours at
37°C. To determine the number of bacteria in ASL,
samples were serially diluted and plated onto agar.
We next measured the alginate mass/bacterial protein
mass under aerobic and anaerobic conditions, using
anaerobic jars and Anaerocult A (Merck KGaA, Darm-
stadt, Germany), with strain PAO1 and 15 environ-
mental P. aeruginosa strains grown on Pseudomonas iso-
lation agar (PIA). After 4 days of growth, the bacteria
were rinsed with water from the plates and the alginate
was measured by the carbazole assay (13). Uronic acids
were quantified using a standard curve of alginate puri-
fied from Macrocystis pyrifera (Sigma Chemical Co.), fol-
lowed by the BCA protein assay to estimate bacterial
protein mass (Pierce Chemical Co., Rockford, Illinois,
USA). In parallel, we visualized P. aeruginosa alginate by
immunostaining PAO1, grown on Columbia sheep
blood agar and fixed on slides, with rabbit antiserum
specific for P. aeruginosa alginate followed by Cy3-
labeled goat anti-rabbit IgG (Dianova).
Finally, we examined the role of nitrate as a terminal
electron acceptor in alginate production under aerobic
versus anaerobic conditions. PAO1 was grown on PIA
agar plates (63 µM nitrate without added nitrate) to
which a range of KNO3 was added (10 µM–100 mM),
and after 4 days of growth, alginate and bacterial pro-
tein was quantitated as above.
Measurements of ASL total nitrate concentration. Total
nitrate (nitrite/nitrate) concentrations in CF and NL
ASL (each CF/NL sample was obtained from pooled ASL
collections from cultures derived from ten or more dif-
ferent subjects) were measured in 10 µl aliquots using a
Nitric Oxide Analyzer (Sievers Model 280b, Ionics
Instrument Business Group, Boulder, Colorado, USA).
Bacteria and in vitro measurements of pO2. Using the
Licox oxygen probe, pO2 was measured at 37°C in sus-
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Figure 1 
P. aeruginosa is localized in intralumi-
nal material of freshly excised CF
airways and binds to mucus. (a)
Thin section of an obstructed CF
bronchus, stained with hematox-
alin/eosin. Note the absence of 
P. aeruginosa on epithelial surface
(black arrow) and presence of 
P. aeruginosa macrocolonies within
intraluminal material (white ar-
rows). Blue gap is an artifact due to
fixation. (b) P. aeruginosa within
macrocolonies in a lung section,
stained with rabbit Ab’s against 
P. aeruginosa. Bars: a, 100 µm; b, 10
µm. (c) Percentage of bacteria
detected at a distance of 2–5 µm or
5–17 µm from the epithelial surface
of lungs from nine CF patients.
Shrinkage artifacts were subtracted
from calculated distances. (d) Scan-
ning electron micrograph of mucus-
coated spheroid derived from CF
respiratory epithelium. P. aeruginosa (white arrow) were enmeshed in mucus (black arrows) following a 2-hour incubation. (e) Immunofluo-
rescent staining of mucins (anti-mucin Ab) bound to P. aeruginosa strain PAO1 in vitro. (f) Spheroid with adherent mucus removed by prewash,
then incubated with P. aeruginosa for 2 hours. Note the absence of bacteria on ciliated epithelial cell surfaces. Bars: d, 0.6 µm; e, 4 µm; f, 2.5
µm. Quantitative comparisons of PAO1 binding revealed higher binding to mucus-coated NES from normal subjects (21.3 ± 10.6 bacte-
ria/NES) versus non–mucus-coated (washed) NES (7.1 ± 0.1 bacteria/NES) (n = 6; 3 normal subjects; P < 0.05). Importantly, these values
were not different for CF NESs (26.4 ± 4.1 bacteria/NES for mucus-coated NESs; 7.7 ± 3.9 bacteria/NES for washed NESs).
pensions of PAO1 grown aerobically in TSB (Oxoid
Ltd.). The pO2 was also measured in heat-inactivated
washed bacterial cultures at 108 CFU/ml.
Statistics. Unless otherwise stated, all data are present-
ed as mean ± SEM. ANOVA (followed by the Tukey test)
was used as appropriate. In the case of nonhomogene-
ity of variance, ANOVA followed by either Dunn’s mul-
tiple comparison test, the Mann-Whitney U test, or the
Wilcoxon signed rank test were used.
Results
P. aeruginosa is intraluminally located in CF airways. Analy-
ses of CF lungs revealed evidence for growth of P. aerug-
inosa predominantly as spherical intraluminal colonies
(Figure 1) (14). We have elected to refer to these spheri-
cal colonies as “macrocolonies,” because many are visi-
ble (>100 µm in diameter) to the naked eye. We used
three separate techniques to test whether macrocolonies
were localized to intraluminal mucus/mucopurulent
material versus epithelial cell surfaces in CF lungs. First,
immunolocalization in thin sections from nine differ-
ent CF lungs revealed most bacteria (94.5%) were local-
ized within the airway lumen 5–17 µm distant from the
epithelial cell surface and the remainder in the zone 2–5
µm from the epithelial surface (Figure 1c). None were
identified in contact with epithelial cells. Second, no P.
aeruginosa bacteria were observed attached to airway
epithelia in TEMs of bronchi from nine CF patients,
containing a total length of 300 mm of bronchial sur-
faces. Third, scanning electron microscopy detected no
bacteria on bronchial epithelia from two patients (total
surface area examined: 116.1 mm2).
P. aeruginosa binding to mucus versus airway epithelial cell
membranes in vitro. We also tested the hypothesis that 
P. aeruginosa binds to mucus rather than airway epithe-
lial cells in vitro. Nasal epithelial spheroids (NESs)
spontaneously produce mucin, a fraction of which
adheres to ciliated cells (9). Incubation of P. aeruginosa
PAO1 with NESs revealed that the bacteria were
enveloped by the mucus attached to NESs (Figure 1d).
Mucin binding was also demonstrated by incubating 
P. aeruginosa with mucins secreted by NESs (Figure 1e).
In contrast, washing NESs to remove adherent mucins
greatly reduced P. aeruginosa binding (Figure 1f).
O2 is depleted within Pseudomonas-infected intraluminal
mucopurulent masses in vivo. The pO2 in CF mucopuru-
lent masses in vivo was measured by inserting an O2
electrode directly into the right upper lobar bronchi of
chronically infected CF patients (Figure 2a). When the
probe was in the bronchial lumen, the pO2 reached
approximately 180 mmHg, a value consistent with the
supplemental O2 administered during bronchoscopy.
Upon probe insertion into the mucopurulent material
obstructing the lobar bronchus, the pO2 declined rap-
idly to a mean value of 2.5 mmHg (Figure 2b).
In vitro analyses of the genesis of O2 gradients in uninfected
ASLs. The diffusion of O2 through liquids is slow com-
pared with air (15) so that the hypoxia measured with-
in the mucopurulent luminal masses could reflect, in
part, restricted O2 diffusion through thickened intra-
luminal liquids. Although bacteria or neutrophils like-
ly consume O2 and contribute to the low pO2 measured
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Figure 2 
Oxygen partial pressure (pO2) CF airways in vivo and in thick films of
ASL on human airway epithelial cultures. (a) pO2 in CF airways. First
30 minutes represents measurement in a nonobstructed region of the
airway lumen. The arrow indicates insertion of oxygen probe into a
mucopurulent mass. The pO2 returned to basal values after probe
retraction from the adherent mass into the nonobstructed airway
region. (b) pO2 in nonobstructed CF airway lumens (L) and CF
mucopurulent masses (M) in vivo. n = 3 CF subjects; *P = 0.001. (c)
Plots of pO2 gradients under thick film conditions at 37°C in NL
(squares; eight cultures/five subjects) and CF cultures (circles; six cul-
tures/four subjects). (d) pO2 gradients under thick film conditions
measured at 4°C in NL (squares; five cultures/three subjects) and CF
cultures (circles; five cultures/three subjects). (e) pO2 gradients in CF
mucus that had accumulated for 48 hours on CF culture surfaces and
had become stationary due to volume hyperabsorption (inverted tri-
angles). Mucus transport was restored in these cultures by addition
of 30 µl PBS, and pO2 gradients remeasured 1–2 hours later (trian-
gles; six cultures; three subjects each). (f) Comparison of pO2 gradi-
ents in NL (squares; nine cultures/six subjects) and PCD (diamonds;
five cultures/two subjects) cultures under thick film conditions. Data
are shown as mean ± SEM. *Significantly different (P < 0.05) from
pO2 at the air-liquid interface (0 µm). †Significant difference 
(P < 0.05) between NL and CF.
in mucopurulent lumenal masses in vivo (see below), it
is possible that the O2 consumption of the underlying
CF epithelium uniquely contributes to mucus O2 gra-
dients before infection.
To test the hypothesis that airway epithelial O2 con-
sumption generates O2 gradients in liquid films that
mimic in height mucus accumulated on CF airway sur-
faces (16), we measured O2 gradients in NL and CF air-
way epithelia covered by an approximately 800-µm thick
ASL (PBS). NL airway epithelia generated measurable O2
gradients at 37°C in this layer (Figure 2c). However, the
pO2 gradient was significantly steeper in CF cultures
(Figure 2c). Both NL and CF ASL O2 gradients were abol-
ished at 4°C, suggesting that the gradients indeed
reflected epithelial O2 consumption (Figure 2d).
Next, we asked whether the presence of mucins with-
in ASL and mucus transport were important determi-
nants of O2 gradients under these thick film condi-
tions. No differences in O2 gradients were observed in
CF cultures with or without rotational mucus trans-
port (Figure 2e). Thus, we conclude that neither the
presence of mucus, nor mixing, which occurs as a con-
sequence of mucus transport in situ (17), are important
contributors to O2 gradients measured within ASL.
Rather, the gradient reflects ASL depth and rate of
epithelial O2 consumption.
Do CF airway epithelia generate disease-specific steeper O2
gradients within ASL? We measured the O2 gradients in
cultures derived from patients with primary ciliary
dyskinesia (PCD), a genetic disease of ciliary motility
characterized by chronic airways infection (18). The
pO2 gradients in PCD ASL resembled that of normal
cultures and were shallower than CF ASL gradients
(compare Figure 2, f and c). Thus, it appears that the
ability to generate steep O2 gradients within ASL
reflected a unique feature of CF airway epithelia.
Will bacteria deposited on mucus surfaces penetrate to hypox-
ic zones in mucus layers? If bacteria contained within
inhaled droplet aerosols deposit and remain on the sur-
face of the mucus layer, then bacteria would be persist-
ently exposed to normoxic environments. Conversely,
if inhaled bacteria move (“swim”) into the mucus layer,
they may face low pO2. Two sets of experiments were
designed to distinguish between these possibilities.
First, we examined the behavior of bacteria con-
tained in small volumes (25 nl), designed to mimic
aerosol droplets, deposited on the surface of CF air-
way epithelial cultures that exhibited rotational
mucus transport. At the earliest time point measura-
ble (3 minutes), motile P. aeruginosa penetrated into
the mucus layer (Figure 3a). We next asked whether
bacterial penetration into mucus reflected bacterial
motility or mucus mixing in the vertical axis during
rotational surface (horizontal) mucus transport (17).
Fluorescently labeled beads deposited on the airway
surface exhibited similar kinetics of penetration into
the mucus layer, suggesting turbulent flow within the
mucus layer accounted for penetration to hypoxic
zones (Figure 3b).
Second, we tested whether motile P. aeruginosa could
penetrate mucus masses adherent to CF airway surfaces.
Within 15 minutes, P. aeruginosa had penetrated deep
into the mucus (compare Figure 3, c with d). In contrast,
fluorescent beads remained on the surface of the mucus
plaque (compare Figure 3, e with f), suggesting that bac-
terial motility was required for P. aeruginosa penetration
into hypoxic zones within stationary mucus masses.
Response of P. aeruginosa to a hypoxic environment. P.
aeruginosa is an aerobic bacterium that will grow under
anaerobic conditions if sufficient terminal electron
acceptors are provided (19–21). Because it is not yet
known what bacterial culture media best mimics
human ASL (mucus), we tested for Pseudomonas
growth under aerobic versus anaerobic conditions,
using ASL harvested from CF and NL cultures. P.
aeruginosa grew equally well in aerobic and anaerobic
conditions (Figure 4a).
To test whether growth of Pseudomonas under anaero-
bic conditions in ASL was supported by NO3– as a ter-
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Figure 3
Localization of P. aeruginosa and beads in transported and station-
ary ASL (mucus) produced by planar CF cultures. Representative
confocal images of ASL (red) fluorescent P. aeruginosa (green) or
green fluorescent beads. P. aeruginosa or beads were added to the air-
liquid interface in 25-nl aliquots by a microsyringe mounted in a
hydraulic micromanipulator. (a) X-Z confocal image of P. aeruginosa
3 minutes after addition to the surface of ASL (mucus) exhibiting
rotational transport. (b) X-Z confocal image of beads 3 minutes
after addition to the surface of mucus exhibiting rotational trans-
port. Note that due to the rapid “tumbling” movement of the mucus
it was not possible to obtain early time-point images of P. aeruginosa
or beads at the air-liquid interface. P. aeruginosa 3 minutes (c) and
15 minutes (d) after addition to stationary mucus. Beads at 3 min-
utes (e) and 15 minutes later (f) after addition to stationary mucus.
Scale bars, 100 µm.
minal electron acceptor, total nitrate concentration was
measured and found to be not different in uninfected
ASL from NL (20 µM) and CF (26 µM) cultures. These
ASL total nitrate concentration values are substantially
lower than those reported for airway secretions collect-
ed in vivo. For example, tracheal secretions from control
subjects have been reported to contain 144–421 µM total
nitrate (22, 23). The higher levels from tracheal secre-
tions could reflect the fact that upper airways produce
more NO than the lower airway regions (24, 25) that are
representative in our cultures (third to sixth generation
bronchi). Importantly, as we found in ASL from NL and
CF cultures, no differences in tracheal secretion total
nitrate concentrations were found between “stable” CF
patients (range 387–421 µM) and controls (22, 23).
We next asked whether the stress of anaerobic envi-
ronments could induce P. aeruginosa to acquire pheno-
typic features that allows it to evade host defenses.
Therefore, we measured P. aeruginosa production of
alginate, an exopolysaccharide involved in P. aeruginosa
biofilm formation, under anaerobic versus aerobic con-
ditions on agar plates (Columbia sheep blood agar, 37
µM total nitrate concentration, and PIA, 63 µM total
nitrate concentration) that contained total nitrates in
concentrations similar to that in ASL. Both immuno-
fluorescence detection of alginate associated with the
bacterial surface (Figure 4b; note thicker alginate coat
in right panel) and quantitative measurement of algi-
nate/bacterial protein mass (Figure 4c) demonstrated
increased alginate production when PAO1 was grown
under anaerobic conditions. A thicker alginate coat
(∼50%) was also observed for PAO1 grown in ASL
under anaerobic versus aerobic conditions.
To test whether the behavior of PAO1 mimicked that
of environmental strains that may infect CF mucus
early in the course of the disease, alginate production
by 15 nonmucoid P. aeruginosa environmental strains,
genetically different by pulsed field gel electrophoretic
analysis, was compared during growth in aerobic ver-
sus anaerobic environments. These strains routinely
produced more alginate under anaerobic (0.191 ± 0.037
µg alginate per microgram of bacterial protein) versus
aerobic (0.022 ± 0.004 µg alginate per microgram of
bacterial protein) growth conditions.
We next tested whether alginate production could, in
part, reflect “stress” of an anaerobic environment with
limiting concentrations of [NO3–] as a terminal electron
acceptor. As shown in Figure 4d, the ratio of alginate to
bacterial protein mass was highest at lower nitrate con-
centrations, including the 63 µM nitrate value of PIA
(no added nitrate) that is most similar to values in ASL.
Finally, we asked whether the introduction of bacte-
ria as O2-consuming elements into mucus contributed
to the magnitude of the O2 gradients observed in vivo
(Figure 2). O2 tensions were reduced when P. aeruginosa
growing in an open glass tube reached densities of
approximately 5 × 106 to 5 × 107 CFU/ml (Figure 4e).
At approximately 3 × 107 CFU/ml, virtually all O2 was
consumed. Modeling of bacterial O2 consumption
(Figure 4f) showed that anaerobic conditions are gen-
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Figure 4
Growth and alginate production of P. aeruginosa under aerobic versus
anaerobic conditions. (a) Growth of P. aeruginosa in NL or CF ASL
under aerobic or anaerobic conditions. Two strains, PAO1 (black
bars) and ATCC 700829 (gray bars), were inoculated (∼100–200 bac-
teria, dashed line) in 30 µl NL or CF ASL and number of bacteria
quantitated 72 hours later. The results presented are from a single
representative experiment of three performed. The differences in the
CFU/ml in the three experiments were less than 0.3 log 10. (b)
Immunofluorescence detection of alginate production by PAO1 after
aerobic (8 hours; left) or anaerobic (12 hours; right) conditions (mag-
nification, ×1,000; bars, 10 µm). (c) Alginate production of PAO1 by
the carbazole assay after growth under anaerobic (black bar) or aer-
obic (white bar) conditions for 4 days without added nitrate. 
*P < 0.05. (d) Alginate production per microgram bacterial protein
mass of PAO1 as a function of the added NO3– to PIA under aerobic
(white bars) and anaerobic (black bars) conditions. (e) pO2 (filled
squares) in an aerobically growing suspension of P. aeruginosa (open
triangles) as a function of time (hours). (f) Mathematical analysis of
depths from air-mucus interface at which pO2 becomes zero for sim-
ulated mucus masses/plaques containing different concentrations of
P. aeruginosa bacteria (colony-forming units per milliliter).
erated at very shallow depths (∼3 µm) in infected
mucus masses when bacterial counts exceed 106
CFU/ml. Thus, the cell-specific O2 gradients within
uninfected mucus accumulating on the CF airway
epithelial surfaces will be exacerbated by the intro-
duction of P. aeruginosa into mucus.
Discussion
Our studies initially focused on the pathogenesis of
established CF airways infection and, taking clues from
these studies, explored whether these variables could
uniquely contribute to the early pathogenesis of P.
aeruginosa infection in CF airways.
Morphometric analyses of freshly excised lungs by
three techniques demonstrated that P. aeruginosa grows
as macrocolonies in the airway intraluminal rather
than the epithelial surface compartment (Figure 1, a–c).
These findings contradict recent hypotheses emanat-
ing from in vitro model systems that focus on high-
salt/defensin inactivation (26) or luminal epithelial cell
binding (4), which predict bacterial infection of CF air-
way epithelial cells themselves (5, 6). However, our data
are consistent with those from animal models that
have demonstrated the adherence of P. aeruginosa to res-
piratory mucus (27–29), and three previous qualitative
studies of CF postmortem lungs that identified 
P. aeruginosa in airway lumens rather than on airway
epithelial cells (30–32). Furthermore, they are also con-
sistent with our studies of NSEs that revealed P. aerug-
inosa preferentially bound to mucus rather than epithe-
lial cell surfaces (Figure 1, d–f). A key extension of the
in vivo characterization of CF airways infection is that
P. aeruginosa occupies an intraluminal niche that is
markedly hypoxic (Figure 2, a–b).
If the CF airways disease reflects infection of mucus,
how is this process initiated and perpetuated? A
sequence consistent with several aspects of the “low vol-
ume/reduced mucus clearance” hypothesis (10, 33) for
CF pathogenesis is outlined in Figure 5. First, as com-
pared with NL airway epithelial function (compare
Figure 5a), data have been reported that CF airway
epithelia excessively absorb Na+ and Cl– (and water)
from the lumen, deplete the periciliary liquid layer
(PCL), and slow/abolish mucus clearance (Figure 5b)
(10, 34, 35). Accelerated Na+ absorption, which reflects
the absence of CFTR’s normal inhibitory activity on
ENaC (36), is fueled by an increased turnover rate of
ATP-consuming Na+-K+-ATPase pumps (37, 38) lead-
ing to two- to threefold increases in CF airway epithe-
lial O2 consumption (39).
Second, persistent mucin secretion into stationary
mucus generates plaques/plugs (16) (Figure 5c). The
combination of thickened mucus and raised O2 con-
sumption by CF epithelia generated steep O2 gradients
within adherent mucus (Figure 2c). Importantly, the
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Figure 5
Schematic model of the pathogenic events hypothesized to lead to
chronic P. aeruginosa infection in airways of CF patients. (a) On nor-
mal airway epithelia, a thin mucus layer (light green) resides atop the
PCL (clear). The presence of the low-viscosity PCL facilitates efficient
mucociliary clearance (denoted by vector). A normal rate of epithe-
lial O2 consumption (QO2; left) produces no O2 gradients within this
thin ASL (denoted by red bar). (b–f) CF airway epithelia. (b) Exces-
sive CF volume depletion (denoted by vertical arrows) removes the
PCL, mucus becomes adherent to epithelial surfaces, and mucus
transport slows/stops (bidirectional vector). The raised O2 con-
sumption (left) associated with accelerated CF ion transport does
not generate gradients in thin films of ASL. (c) Persistent mucus
hypersecretion (denoted as mucus secretory gland/goblet cell units;
dark green) with time increases the height of luminal mucus mass-
es/plugs. The raised CF epithelial QO2 generates steep hypoxic gra-
dients (blue color in bar) in thickened mucus masses. (d) P. aerugi-
nosa bacteria deposited on mucus surfaces penetrate actively and/or
passively (due to mucus turbulence) into hypoxic zones within the
mucus masses. (e) P. aeruginosa adapts to hypoxic niches within
mucus masses with increased alginate formation and the creation of
macrocolonies. (f) Macrocolonies resist secondary defenses, includ-
ing neutrophils, setting the stage for chronic infection. The presence
of increased macrocolony density and, to a lesser extent neutrophils,
render the now mucopurulent mass hypoxic (blue bar).
steep pO2 gradient in ASL/mucus was specific for CF
epithelia because it was not reproduced in cultures
from another genetic airways disease with an infectious
phenotype, PCD (Figure 2f).
Third, bacteria deposited on thickened mucus can
penetrate into hypoxic zones (Figure 5d). When the
normal rotational mucus transport ceased due to
excessive volume absorption, the vertical “currents”
within transported mucus were abolished, but motile
P. aeruginosa still penetrated thickened mucus (Figure
3, c and d). Note that environmental P. aeruginosa
strains such as those that characterize early infection
are motile and would likely penetrate mucus readily.
Fourth, P. aeruginosa can grow in hypoxic/anaerobic
CF mucus (Figure 4a). In part, growth under anaero-
bic conditions may be supported by the terminal elec-
tron acceptor, nitrate (∼20 µM), contained in ASL. Fur-
thermore, we show that increased alginate production
was a characteristic feature of PAO1 strains in
response to hypoxia, particularly with growth in low
concentrations of nitrate that mimic ASL (Figure 4,
b–d), and this characteristic is also a feature of envi-
ronmental P. aeruginosa strains. We speculate that the
increased alginate formation may represent a stress
response to hypoxia that is part of the process that
forms biofilmlike macrocolonies, the predominant
phenotype of P. aeruginosa in CF airways (3). Interest-
ingly, Staphylococcus aureus also responds to the hypox-
ic environment of CF mucus with a switch from non-
mucoid to a mucoid phenotype (40, 41).
Finally, the capacity of P. aeruginosa to proliferate in
hypoxic mucus will generate fully hypoxic (anaerobic)
conditions in patients with persistent CF airways infec-
tion (Figure 1, Figure 4, e and f, and Figure 5e). Hassett
et al. reported that P. aeruginosa alginate production was
maintained by anaerobic conditions (21). The reduced
O2 tension in the mucopurulent intraluminal contents
of CF airways may, therefore, be one variable contribut-
ing to the persistence of P. aeruginosa macrocolonies in
CF airways. The consequences of the macrocolony
growth state have been explored in detail and include
resistance to antibiotics (42) and host phagocyte killing
(Figure 5f) and (42, 43), all of which contribute to the
persistence of P. aeruginosa infection and the chronic
destructive airways disease characteristics of CF.
In summary, our data demonstrate that the P. aerugi-
nosa infection of CF airways occurs within the luminal
(mucus) rather than the epithelial cell surface com-
partment. Thus, we speculate that mucus clearance is
a key feature of innate lung defense (44), and a funda-
mental defect leading to chronic CF lung infections is
the failure to effectively clear mucus that contains
bound bacteria from the lung (10). Hypoxic gradients
exist within poorly cleared/adherent mucus, conse-
quent to CF-specific increases in epithelial O2 con-
sumption, and inhaled P. aeruginosa respond to hypox-
ic mucus with alginate production and macrocolony
formation, which allows them to evade host defenses
and produce a chronic destructive lung disease. These
data lead us to conclude that therapeutic strategies to
treat CF lung disease should include novel drugs
designed to clear the lung of retained mucus
plaques/plugs, which initiate and perpetuate CF lung
disease, and antibiotics that effectively treat P. aerugi-
nosa growing under hypoxic/anaerobic conditions.
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